Equities research analysts expect Inogen, Inc (NASDAQ:INGN) to report sales of $60.29 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Inogen’s earnings. The lowest sales estimate is $59.97 million and the highest is $60.61 million. Inogen posted sales of $54.57 million during the same quarter last year, which suggests a positive year over year growth rate of 10.5%. The company is expected to issue its next quarterly earnings report on Thursday, August 3rd.

On average, analysts expect that Inogen will report full-year sales of $60.29 million for the current year, with estimates ranging from $237.50 million to $240.20 million. For the next financial year, analysts anticipate that the firm will post sales of $280.36 million per share, with estimates ranging from $277.21 million to $283.88 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Inogen.

Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, May 9th. The medical technology company reported $0.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.15. Inogen had a net margin of 9.32% and a return on equity of 11.67%. The business had revenue of $52.50 million for the quarter, compared to analysts’ expectations of $49.06 million. During the same quarter in the previous year, the business posted $0.12 earnings per share. The business’s revenue was up 22.1% compared to the same quarter last year.

Several research firms have recently commented on INGN. Zacks Investment Research lowered Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 11th. J P Morgan Chase & Co lifted their price target on Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. Needham & Company LLC lifted their price target on Inogen from $96.00 to $108.00 and gave the stock a “strong-buy” rating in a report on Friday, June 9th. Stifel Nicolaus lifted their price target on Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a report on Wednesday, May 10th. Finally, Sidoti began coverage on Inogen in a report on Tuesday, April 18th. They set a “neutral” rating and a $79.00 price target on the stock. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $91.60.

In related news, insider Scott Wilkinson sold 23,437 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $88.06, for a total transaction of $2,063,862.22. Following the completion of the sale, the insider now directly owns 54,088 shares of the company’s stock, valued at approximately $4,762,989.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $91.54, for a total value of $228,850.00. Following the sale, the executive vice president now directly owns 4,833 shares of the company’s stock, valued at $442,412.82. The disclosure for this sale can be found here. Insiders have sold a total of 97,848 shares of company stock valued at $8,631,966 over the last three months. Corporate insiders own 5.31% of the company’s stock.

Several hedge funds have recently modified their holdings of INGN. Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in shares of Inogen during the second quarter worth about $2,052,000. Aperio Group LLC acquired a new stake in shares of Inogen during the second quarter worth about $854,000. Rockefeller Financial Services Inc. increased its stake in shares of Inogen by 5.2% in the second quarter. Rockefeller Financial Services Inc. now owns 309,755 shares of the medical technology company’s stock worth $29,557,000 after buying an additional 15,377 shares during the last quarter. Eqis Capital Management Inc. acquired a new stake in shares of Inogen during the second quarter worth about $529,000. Finally, State of Alaska Department of Revenue increased its stake in shares of Inogen by 79.4% in the second quarter. State of Alaska Department of Revenue now owns 3,212 shares of the medical technology company’s stock worth $306,000 after buying an additional 1,422 shares during the last quarter.

WARNING: “Inogen, Inc (NASDAQ:INGN) Expected to Post Quarterly Sales of $60.29 Million” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/22/inogen-inc-nasdaqingn-expected-to-post-quarterly-sales-of-60-29-million.html.

Inogen (NASDAQ INGN) traded down 1.58% on Friday, reaching $95.22. 142,600 shares of the company’s stock were exchanged. The firm has a market cap of $1.96 billion, a PE ratio of 85.17 and a beta of 1.04. The firm has a 50 day moving average price of $93.50 and a 200 day moving average price of $79.08. Inogen has a one year low of $50.01 and a one year high of $97.71.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.